The series C sets Amplyx up to take its lead broad-spectrum antifungal candidate into phase 2 later this year.

The series C tees Milestone up to test its intranasal calcium channel blocker etripamil in patients with paroxysmal supraventricular tachycardia. 

More biopharma news of note for Thursday.

Canaan will continuw the strategy that has delivered it paydays as companies including J&J and Teva have snapped up pieces of its portfolio.

The series B equips the biotech to take its lead treatment for multidrug-resistant Gram‐negative infections through clinical trials.

Rodeo has got off a $5.9 million series A financing round with a list of all-stars as backers.

Sarepta CEO Doug Ingram aims to raise $250 million in a public stock offering as the company looks beyond its first product, DMD therapy Exondys 51.

Check out the rest of Thursday's news of note.

NeuroVia gets $14 million to treat rare CNS disorder X-linked adrenoleukodystrophy.

Venture Capital